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Surgical techniques in dental and maxillofacial surgery request fast bone tissue regeneration, so there is a significant need to
improve therapy for bone regeneration. Several studies have recently underlined the importance of nucleotides and nucleosides
to increase cell proliferation and activity; in particular, the ability of polydeoxyribonucleotide (PDRN) to induce growth and
activity of human osteoblasts was demonstrated. Sodium-DNA is the deoxyribonucleic acid (DNA) extracted from the gonadic
tissue of male sturgeon and then purified, depolymerized, and neutralized with sodium hydroxide. To date, there are no evidences
about the use of Sodium-DNA for bone tissue regeneration. Consequently, our question is about the efficacy of Sodium-DNA in
bone healing. For testing the role of Sodium-DNA in bone healing we used a rat calvarial defect model. Sodium-DNA at different
concentrations used alone or in associationwith Fibrin and/or Bio-Osswas used for healing treatments and the bone healing process
was evaluated by histomorphometric and immunohistochemical analyses. Our results suggested a positive effect of Sodium-DNA
in bone regeneration, providing a useful protocol and a model for the future clinical evaluation of its osteogenic properties.
1. Introduction
Surgical techniques in dental and maxillofacial surgery
request adequate and fast bone tissue regeneration. In recent
decades, different surgical approaches have been proposed to
manage different types of bone defects using a variety of graft
materials with different osteoconductive, osteoinductive, and
osteogenic properties. Nowadays, autologous bone graft and
allograft are the most used devices [1–8], but the limited
tissue availability and the risk of donor site morbidity (for
autologous graft) and the possibility of host rejection or
disease transmission (for allograft) represent some important
limitations.
Several studies have underlined the importance of action
of nucleotides and nucleosides to increase proliferation and
activity of different cell types [9–12] by acting in synergy
with several growth factors (i.e., epidermal growth factor,
EGF, platelet-derived growth factor, PdGF, and fibroblast
growth factor, FGF), modulating cytokines and growth factor
production, and influencing immunological response [13].
Polydeoxyribonucleotide (PDRN) is a compoundholding
polymers of different length obtained from the spermof some
animal species and used as a tissue repair-stimulating agent.
Its effects on cell growth and activity have been demonstrated
in different cell lines [12–18] and tissues [18–27]. In particular,
PDRN is cleaved by active cell membrane enzymes, providing
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a source for deoxyribonucleotides and deoxyribonucleosides
that can increase cell proliferation and activity stimulating
nucleic acid synthesis through the salvage pathway [28]
and/or binding and activating the purinergic receptors [9,
20, 23]. Evidences suggested that PDRN, acting as an agonist
on adenosine A
2A receptor, was able to improve healing
process by increasing the expression of vascular endothelial
growth factor (VEGF) and angiopoietin-1, an angiogenic
factor involved in the stabilization and maturation of newly
formed vessels [12, 20, 23, 25, 29]. Moreover, an important
role in maintaining cell proliferation and in preventing the
exaggerated hyperproliferation that may be associated with
tissue repair has been also suggested [19].
In bone tissue regeneration, PDRN was reported to play
an important role acting as osteoblast growth stimulator. In
this way, purinergic receptors seem to be partially involved in
the rapid proliferation, new bone formation, and a reduction
of bone healing time, as confirmed after treatments with
specific purinergic receptor inhibitors [9, 13, 18, 28]. PDRN
effect on bone regeneration was also demonstrated in an
experimental study on rats and mice, in which the effect of
PDRN used alone or in association with other materials was
reported [30, 31].
Sodium-DNA is the deoxyribonucleic acid (DNA)
extracted from the gonadic tissue of male sturgeon and
then purified, depolymerized, and neutralized with sodium
hydroxide. Sodium-DNA passes through the cell membrane
by pinocytosis and acts as a donor of purine and pyrimidine
bases, which are key molecules for cell vitality. To date, there
are some evidences about its efficacy in the treatment of skin
lesions [32] but there are no literature data concerning its
potential effects in dental and maxillofacial surgery.
Therefore, the aim of this study was to evaluate the
efficacy of Sodium-DNA used alone or in association with
Fibrin and/or Bio-Oss (Geistlich, Wolhusen, Switzerland), a
bone substitute material obtained from the mineral portion
of bovine bone, for repairing bone defect in a rat calvarial
experimental model. In addition to histomorphometric eval-
uation, we examined, immunohistochemically, threemarkers
of bone regeneration: RUNX2, an essential transcription
factor for osteoblast differentiation and for extracellular
matrix gene expression [33, 34]; osteocalcin (OCG3), a
marker of osteocalcin, which is produced by osteoblasts and
is implicated in bone mineralization and calcium ion home-
ostasis [35]; osteopontin (OPN), a phosphoglycoprotein of
the extracellularmatrix of bone tissue that plays an important
role in bone resorption as is expressed by many other cells
[36, 37].
2. Materials and Methods
2.1. Experimental Design. The experimental protocol was
approved by the Local Ethical Committee on Animal Care
and Use of the University of Brescia and by the Italian
Ministry of Health. Sixty male Wistar rats (Harlan, Milan,
Italy) weighing between 320 to 420 g each were used in
this study. The animals were held in separate cages in a
ventilated stand, under standardized air and light conditions
at a constant temperature of 22∘C with a 12-hour light/day
cycle.They had free access to tap drinkingwater and standard
laboratory food pellets.
The animals were randomly divided into 6 groups (10
animals for each group). Each group was subdivided in
relation to the different time treatment in two subgroups (30
and 60 days) of 5 animals each. The animals of Group III,
IV, V, and VI were treated differently for the right osteotomy
(A) and the left osteotomy (B). Following, we reported
experimental design.
Group I. Control: the defects were unfilled.
Group II. Fibrin: the defects were filled with Fibrin Glue
(Tisseel, Baxter AG, Vienna, Austria).
Group III (A-B). (A) Bio-Oss: the defects were filled with
Bio-Oss (Geistlich Biomaterials, Wolhusen, Switzerland); (B)
Fibrin + Bio-Oss: the defects were filled by a mixture of both.
Group IV (A-B). (A) Fibrin + DNA-Na (Sanaryn, Veritas srl,
Brescia, Italy): the defects were filled by amixture of both; (B)
Fibrin + vehicle (glycerol, silanol mannuronate, and nisin) of
DNA-Na: the defects were filled by a mixture of both.
GroupV (A-B). (A) Bio-Oss +DNA-Na: the defects were filled
by a mixture of both; (B) Bio-Oss + vehicle of DNA-Na: the
defects were filled by a mixture of both.
Group VI (A-B). (A) Fibrin + Bio-Oss + DNA-Na: the defects
were filled by a mixture of all; (B) Fibrin + Bio-Oss + vehicle
of DNA-Na: the defects were filled by a mixture of all.
2.2. Surgical Procedure. The animals were anesthetized with
an intraperitoneal injection of Zoletil 100 (60mg/kg body
weight; Virbac, France) containing a mixture of tiletamine
and zolazepam. The dorsal region of the skull was shaved
and the head of the rat was positioned in a cephalostat
during the operative procedure and aseptically prepared for
surgery. A middle skin incision from the nasofrontal area to
the external occipital protuberance was performed. The skin
and underlying tissues, including the temporalismuscle, were
reflected laterally to expose the full extent of the calvaria.The
periosteum surrounding the defect was removed to prevent
periosteum osteogenesis. Two symmetrical full-thickness 5 ×
8mm bone skull defects were made on each parietal region,
lateral to the sagittal suture, using piezoelectric ultrasonic
bone surgery under constant irrigation with sterile saline
solution, which allows a selective cut of only mineralized
structures without causing bone necrosis by heating [38].
The dura mater was preserved. This experimental surgical
protocol represented a critical size defect, resulting in no
spontaneous closure of the bone defect, not even reaching
50% of the area after 16 weeks of observation [39]. In order
to minimize the number of animals used for this study,
right and left osteotomy were made according to the exper-
imental design. Furthermore, to ensure the same volume
of test treatments, the defects were filled using stainless-
steel syringes. At the end of the procedures, the flap of each
animal was closed with silk sutures. After 30 or 60 days from
surgery, the animals were sacrificed and the tissue within the
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original surgical defect area was removed.The tissue samples
were fixed in 10% formalin, decalcified in Osteodec (Bio-
Optica, Milan, Italy), and embedded in paraffin according
to the standard procedures. Serial sections (7𝜇m) were cut
longitudinally by amicrotome, starting from the center of the
original surgical defect.
2.3. Histomorphometric Analysis. Histomorphometric anal-
ysis was performed to evaluate the percentage of new bone
formation within the bone defect area. Sections were stained
with Masson-Goldner Trichrome (Merck KGaA, Darmstadt,
Germany). All sections were evaluated under an optical
microscope (Olympus, Milan, Italy) by two investigators
unaware of the group assignment.The following criteria were
applied to standardize the histomorphometric analysis: (1)
the total defect area was identified by the anterior and pos-
terior margin of the surgical defect area and was delimited;
(2) the area of newly formed bone was delineated within the
selected total area.
Percentage of new bone (%NB) formation was calculated
as area of newly formed bone expressed as percentage of
the total defect area. Digitally fixed images were randomly
analyzed using an image analyzer (Image Pro Premier 9.1;
Immagini e Computer, Milan, Italy).Themeasurements were
made as percentage of area in five sections for each sample.
2.4. Immunohistochemical Analysis. Tissue sections were
processed for immunohistochemical analysis to detect
RUNX2, osteocalcin (OCG3), and osteopontin (OPN).
Before the immunohistochemical assays, the sections
were deparaffined, hydrated, and heat treated in 0.05M
EDTA buffer pH 8.0 (Bio-Optica, Milan, Italy) for antigen
unmasking at 98∘C for 20 minutes and RT for 20 minutes.
Endogenous peroxidase activity was blocked by incubation
with a solution of 3% hydrogen peroxide. Sections were
immunostained with the following monoclonal antibod-
ies: RUNX2 (mouse monoclonal, Abcam, Cambridge, UK);
OCG3 (rabbit polyclonal, Abcam, Cambridge, UK); OPN
(rabbit polyclonal, Abcam, Cambridge, UK). All sections
were processed using UltraVision Quanto Detection Sys-
tem HRP (Thermo Scientific, Bio-Optica, Milan, Italy) and
diaminobenzidine (Amresco, Prodotti Gianni, Milan, Italy).
Section incubated without the primary antibody served as
negative control.
Quantitative analysis of immunopositivity was per-
formed to calculate the percentage area of immunostaining
within the total defect area. The analysis was performed
blindly, using an optical light microscope (Olympus, Ger-
many). Digitally fixed images of slices were analyzed using an
image analyzer (Image Pro-Plus 4.5.1; Immagini e Computer,
Milan, Italy). The measurements were made as percentage of
area in five sections for each sample (five random fields for
section).
2.5. Statistical Analysis. Quantitative values of histomorpho-
metric and immunohistochemical analysis were reported
as mean ± standard error (SE). Statistical analysis was
performed using one-way analysis of variance (ANOVA test)
with Bonferroni correction. The significance level was set as
𝑃 < 0.05.
3. Results
Experimental design also included treatments with vehicle
of DNA-Na (Groups IVB, VB, and VIB) to exclude any of
its possible effects on new bone formation. All these groups
showed similar values with the groups treated with Fibrin
alone (Group II), Bio-Oss alone (Group IIIA), or a combi-
nation of Fibrin and Bio-Oss (Group III-B). Therefore, we
decided not to consider these groups in the data processing
step of this study.
3.1. Histomorphometric Analysis. Histomorphometric anal-
ysis was performed in order to quantify the percentage of
new bone (% NB) formation within the total defect area.
The results showed a significant increase after 60 days with
respect to 30 days for all groups, excluding the Control
group. Comparing the groupswithin the same time treatment
(Groups II, III, IV, V, and VI), we observed a significant
increase of % NB with respect to respective Control (Group
I), after both 30 and 60 days from surgery. The significantly
highest value of % NB was found in Fibrin + Bio-Oss +
DNA-Na group after 60 days from surgery (Group VIA).
Quantitative data were reported in Figure 1.
3.2. Immunohistochemical Analysis. Immunohistochemical
analysis was used to investigate the immunolocalization of
some markers of bone regeneration: RUNX2, osteocalcin
(OCG3), and osteopontin (OPN). Negative control treated
without the primary antibodies showed no positive staining
(data not shown).
3.2.1. RUNX2. Immunohistochemical analysis of RUNX2
showed intracellular localization of immunostaining. No
immunopositivitywas observed inmature bone tissue.Quan-
titative analysis of immunostaining revealed a significant
increase after 30 days in all groups treated with Fibrin
(Groups II, IIIB, IVA, and VIA) respect to the others (Groups
I, IIIA, and VA). A decrease in RUNX2 immunostaining was
observed at 60 days with respect to 30 days for each group;
this decrease was significant in the groups treatedwith Fibrin.
No significant difference was observed at 60 days among all
groups. Quantitative data were reported in Figure 2.
3.2.2. OCG3. OCG3 immunostaining was localized in the
osteoblasts that lied on the new bone surface and in the
osteocyte lacunae. Quantitative evaluation showed a signif-
icant increase after 60 days from surgery, for all groups,
excluding the control group. However, a significant increase
was observed in all groups with respect to their Controls
(Group I), after both 30 and 60 days from surgery.Thehighest
value was found in Fibrin + Bio-Oss + DNA-Na group after
60 days from surgery (Group VIA). Quantitative data were
reported in Figure 3.
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Group IIIB: ＆Ｃ＜ＬＣＨ + ＂ＣＩ-Oss
Group IVA: ＆Ｃ＜ＬＣＨ + ＄．！-Na
Group VIA: Fibrin + Bio-Oss + DNA-Na
Figure 1: A–G: Masson-Goldner Trichrome at 60 days (up: low-magnification images; down: high-magnification images). ∗New bone. B:
Bio-Oss; n-MT: nonmineralized tissue. Below: quantitative analysis of percentage of new bone formation (% NB) at 30 days (gray) and 60
days (black). ∗𝑃 < 0.05 versus Control (Group I) 30 days; ∗∗𝑃 < 0.05 versus Control (Group I) 60 days; ∘𝑃 < 0.05 versus 30 days into each
group; ∧𝑃 < 0.05 versus all other groups.
3.2.3. OPN. Immunohistochemical analysis of OPN showed
intracellular localization of immunostaining. A marked sig-
nal was observed within the cells scattered in nonmineralized
tissue. Quantitative analysis showed a significant increase in
all groups with respect to their controls, after both 30 and 60
days from surgery. However, significant highest values were
found at 30 days and that came down to a significant decrease
at 60 days in all groups, including the Control group (Group
I). Quantitative data were reported in Figure 4.
4. Discussion
This study represents the largest in vivo study evaluating the
effects of Sodium-DNA treatment in the context of bone
regeneration.We used a rat calvarial defectmodel to evaluate,
by histomorphometric and immunohistochemical point of
view, bone healing effect of Sodium-DNA combined with or
without Fibrin and/or Bio-Oss.
Our starting point was some literature evidences about
the effects of PDRN on osteoblast proliferation and bone
healing process [13, 30, 31]; in addition, there were some data
about Sodium-DNA as skin repair active principle [32].
Our histomorphometric results showed a significant
increase in bone regeneration using the combination of
Fibrin + Bio-Oss + DNA-Na after 60 days from surgery. This
could be explained considering the different properties for
each material.
A “good material” for bone regeneration, in fact, should
have osteoinductive, osteoconductive, and osteogenic prop-
erties at the same time [40, 41]: the combination among Fib-
rin, Bio-Oss, and DNA-Na could meet these characteristics.
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Group VA: Bio-Oss + DNA-Na
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Group I: Control
Group VIA: Fibrin + Bio-Oss + DNA-Na
Group IIIB: ＆Ｃ＜ＬＣＨ + ＂ＣＩ-Oss
Group IVA: ＆Ｃ＜ＬＣＨ + ＄．！-Na
Figure 2: A–G: RUNX2 immunohistochemistry at 30 days. H: high resolution detail. Below: quantitative analysis of percentage of RUNX2
immunostaining at 30 days (gray) and 60 days (black). ∗𝑃 < 0.05 versus Control (Group I), Bio-Oss (Group IIIA), and Bio-Oss + DNA-Na
(Group VA); ∘𝑃 < 0.05 versus 30 days into each group.
Combining Fibrin glue and bone granules we had differ-
ent benefits. First, it produced a mouldable material that was
surgical handling, and then the Fibrin permitted cementing
the granules into the implant site. However, in addition to
the mechanical aspect of the composite, it was suggested
that the combination might promote bone regeneration [42–
45]. Consequently, Bio-Oss provided an osteoconductive
site for the bone tissue growing and Fibrin represented the
osteoinductive glue, according to the literature data reporting
both the osteoconductivity of Bio-Oss [46, 47] and the effect
of Fibrin sealant or Fibrin glue in osteoinductive process [42–
45].
In addition, our data suggested that, among the three
biologic mechanisms that provide a rationale for bone graft-
ing, osteogenesis could be promoted by Sodium-DNA. This
hypothesis was supported by other previous data about the
effect of PDRN as osteoblast growth stimulator. In particular,
these studies showed that PDRN action could be partially
due to a stimulation of the purinergic system mediated by
A
2
purinoreceptors, suggesting its possible use as osteoblast
stimulator for repairing bone defects [13, 28]. Moreover,
PDRN effect on bone regeneration was also demonstrated in
an experimental study on rats andmice, in which the effect of
PDRN used alone or in association with other materials was
reported [30, 31].
Furthermore, our immunohistochemical results gave us
information about the activation of bone regenerative pro-
cess. We investigated three markers: RUNX2, OCG3, and
OPN.
RUNX2 is a transcription factor involved in osteoblastic
differentiation and skeletal morphogenesis. It is essential for
the osteoblast maturation and both intramembranous and
6 BioMed Research International
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Group VA: Bio-Oss + DNA-NaGroup I: Control
Group IIIB: ＆Ｃ＜ＬＣＨ + ＂ＣＩ-Oss
Group IVA: ＆Ｃ＜ＬＣＨ + ＄．！-Na
Group VIA: Fibrin + Bio-Oss + DNA-Na
Figure 3: A–G: OCG3 immunohistochemistry at 60 days. H: high resolution detail. Below: quantitative analysis of percentage of OCG3
immunostaining at 30 days (gray) and 60 days (black). ∗∗𝑃 < 0.05 versus Control (Group I) 30 days; ∗∗𝑃 < 0.05 versus Control (Group I) 60
days; ∘𝑃 < 0.05 versus 30 days into each group; ∧𝑃 < 0.05 versus all other groups.
endochondral ossification. It can directly stimulate tran-
scription of osteoblast-related genes such as those encod-
ing osteocalcin [33, 34]. RUNX2 is upregulated in imma-
ture osteoblasts, and then it is downregulated in mature
osteoblasts [48]. Carroll and collaborators showed that
purine (i.e., cAMP) was needed for full upregulation of
RUNX2 and/or that finer tuning of cAMP levels is important
for the Control of RUNX2 expression [49]. These studies
supported our results; in fact, we found highest RUNX2
immunopositivity after 30 days from surgery, especially in
Fibrin treated groups. This last point could be due to the
osteoinductive property of the Fibrin that led to recruitment
of the mesenchymal cells and to activation of RUNX2 and,
consequently, to osteoblast differentiation.
OCG3 is amarker of osteocalcin. Osteocalcin is produced
by osteoblasts during bone formation and it is implicated
in bone mineralization and calcium ion homeostasis [35].
OCG3 immunostaining showed time-dependent increase in
all experimental groups; the highest value was observed
after 60 days in Fibrin + Bio-Oss + DNA-Na group. This
result was in accordance with our histomorphometric data.
Therefore, we could assume that Sodium-DNA, together with
osteoinductive and osteoconductive properties of Fibrin and
Bio-Oss, could improve osteogenesis.
OPN is a phosphoglycoprotein of the extracellular matrix
of bone tissue that is also present in other different cells,
such as macrophages, T lymphocytes, smooth muscle cells,
and epithelial and ganglion cells [36, 37]. Our data showed
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Group I: Control
Group IIIB: ＆Ｃ＜ＬＣＨ + ＂ＣＩ-Oss
Group IVA: ＆Ｃ＜ＬＣＨ + ＄．！-Na
Group VIA: Fibrin + Bio-Oss + DNA-Na
Figure 4: A–G: OPN immunohistochemistry at 30 days. H: high resolution detail. Below: quantitative analysis of percentage of OPN
immunostaining at 30 days (gray) and 60 days (black). ∗∗𝑃 < 0.05 versus Control (Group I) 30 days; ∗∗𝑃 < 0.05 versus Control (Group
I) 60 days; ∘𝑃 < 0.05 versus 30 days into each group.
significant higher values of OPN immunostaining after 30
days from surgery in all experimental groups; on the other
hand, a significant decrease was observed after 60 days.
Considering that OPN is necessary for bone remodeling and
that it is suppressed when bone formation is stabilized, our
supposition was that, during the earlier regenerative phases,
OPN was expressed by granulation tissue (composed of
fibroblasts, myofibroblasts, inflammatory cells, extracellular
matrix, and newly formed vessels), as previously suggested
[50].
5. Conclusion
These results suggested a positive effect of Sodium-DNA in
bone regeneration, providing a useful protocol and a model
for the future clinical evaluation of its osteogenic properties
and an alternative method of therapy for patients suffering
from bone defects that are both effective and economic.
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